Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system. Germantown, Maryland-based Senseonics offered a previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days). Europe already had a 180-day Senseonics CGM system available (Eversense […]
Technology
Data supports Beta Bionics’ iLet bionic pancreas
Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c. Dr. Roy W. Beck and clinical investigators presented the results of the multi-center, randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Read: The biggest stories […]
DarioHealth closes $50M loan facility with OrbiMed
DarioHealth (Nasdaq:DRIO) announced today that it closed a senior secured term loan facility worth up to $50 million. OrbiMed, a leading healthcare investor, will provide non-dilutive capital to fund the continued development of New York-based DarioHealth’s digital health platform for managing chronic diseases, including diabetes. According to a news release, the five-year, $50 million facility includes […]
Pear Therapeutics reports positive real-world data for chronic insomnia treatment
Pear Therapeutics (Nasdaq:PEAR) today announced real-world data from a trial of its Somryst prescription digital therapeutic (PDT). Data showed that Somryst, the only FDA-authorized PDT for treating chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and at six-months follow-up. Boston-based Pear Therapeutics presented results at the […]
The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions
For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott, Insulet and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. […]
Digital therapeutics developer Better Therapeutics names new CEO
Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Frank Karbe as its new president and CEO. San Francisco-based Better Therapeutics develops prescription digital therapeutics (PDTs) based on nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases. Karbe will join the company as president and CEO and will serve as a member […]
Dexcom CEO expects ‘science boom’ with CGM, automated insulin delivery
With the G7 nearing FDA clearance, Dexcom leadership foresees major innovations for integrated automated insulin delivery down the line. Kevin Sayer began thinking about automated insulin delivery all the way back in 1994 when he was working at MiniMed. Nearly 30 years later, as CEO of Dexcom (Nasdaq:DXCM), that space continues to pique his interest. […]
Tandem reports positive data for t:slim X2 insulin pump with Control-IQ technology
Tandem Diabetes Care (Nasdaq:TNDM) announced today that real-world data supports its t:slim X2 insulin pump with Control-IQ technology. Data from the ongoing real-world Control-IQ observational (CLIO) study demonstrating immediate and sustained benefits in a diverse cohort of participants was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. “Our Control-IQ technology continues […]
One Drop studies show improved attitudes toward CGM, diabetes management platform
One Drop announced positive data from multiple studies evaluating the opinions of people with diabetes on continuous glucose monitoring. New York-based One Drop presented new research about attitudes and adoption of continuous glucose monitors (CGMs) among people with type 2 diabetes at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Participants in […]
Virta Health reports positive results from diabetes reversal study
Virta Health announced today that its diabetes reversal treatment demonstrated improvements in those with type 2 diabetes. San Francisco-based Virta Health launched in 2017 with the goal of reversing Type 2 diabetes using its technology platform to enable personalized remote care. Virta’s offerings include physician supervision, health coaches, an app and biomarker tracking tools, as well […]
